(Q44591897)

4 December 2017

title

The business case for preventing ventilator-associated pneumonia in pediatric intensive care unit patients (English)

1 reference

4 December 2017

1 reference

1 reference

1 reference

Richard J Brilli

1

1 reference

4 December 2017

Karen W Sparling

2

1 reference

4 December 2017

Michael R Lake

3

1 reference

4 December 2017

John Butcher

4

1 reference

4 December 2017

Sarah S Myers

5

1 reference

4 December 2017

Marta D Clark

6

1 reference

4 December 2017

Alma Helpling

7

1 reference

4 December 2017

Mary E Stutler

8

1 reference

4 December 2017

publication date

1 November 2008

1 reference

Joint Commission Journal on Quality and Patient Safety

4 December 2017

published in

1 reference

4 December 2017

volume

34

1 reference

4 December 2017

issue

11

1 reference

4 December 2017

page(s)

629-638

1 reference

The business case for quality: case studies and an analysis

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Ventilator-associated pneumonia in pediatric intensive care unit patients: risk factors and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Impact of ventilator-associated pneumonia on resource utilization and patient outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Cost effectiveness in treating ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Effect of ventilator-associated pneumonia on mortality and morbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Nosocomial pneumonia: a cost-of-illness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Clinical and economic consequences of ventilator-associated pneumonia: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

The use of preventable adverse outcomes to study the quality of child health care. A new application of case-control research

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Feeding back surveillance data to prevent hospital-acquired infections

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Prolongation of hospital stay and extra costs due to ventilator-associated pneumonia in an intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Effectiveness of a nationwide nosocomial infection surveillance system for reducing nosocomial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

The cost-shift payment 'hydraulic': foundation, history, and implications.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Implementation of an institutional program to improve clinical and financial outcomes of mechanically ventilated patients: one-year outcomes and lessons learned.

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

The business case for quality at a university teaching hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia : potential economic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1553-7250%2808%2934080-X

7 January 2021

10.1016/S1553-7250(08)34080-X

Identifiers

DOI

1 reference

4 December 2017

1 reference